Skip to main content
Shoulder & Elbow logoLink to Shoulder & Elbow
. 2018 May 14;11(2 Suppl):67–72. doi: 10.1177/1758573218774317

Blood transfusion rates following shoulder arthroplasty in a high volume UK centre and analysis of risk factors associated with transfusion

PJ Dacombe 1,, JV Kendall 1, PAS McCann 1,2, IN Packham 1, PP Sarangi 1, MR Whitehouse 1,3,4, MA Crowther 1
PMCID: PMC6688153  PMID: 31447947

Abstract

Aims

To determine the blood transfusion rates following shoulder arthroplasty and to establish risk factors associated with increased risk of transfusion.

Materials and methods

All shoulder arthroplasty cases performed between January 2012 and March 2017 in a tertiary upper limb unit were identified. Patients who received perioperative tranexamic acid were excluded. Retrospective review of case notes was completed to identify transfusion rate and risk factors. Univariate and multivariate analysis were performed to analyse the association between risk factors and transfusion rate.

Results

Five hundred and thirty-seven shoulder arthroplasties performed in 474 patients were included. Peri- or post-operative transfusion was required in 21 cases (3.9%). Univariate analysis suggested significant association with age (p = 0.005), female sex (0.015), preoperative haemoglobin/haematocrit (p < 0.001), perioperative drop in haemoglobin (p < 0.001), ASA grade (p < 0.001) and transfusion rate. Only perioperative drop in haemoglobin (p < 0.001) and American Society of Anaesthesiologist score (ASA) grade (p = 0.039) retained significance on multivariable analysis.

Conclusions

The blood transfusion rate following shoulder arthroplasty was 3.9%. Greater perioperative drop in haemoglobin and higher ASA grade were associated with increased risk of transfusion on multivariate analysis.

Keywords: shoulder, arthroplasty, transfusion, outcome, complication

Introduction

Rates of shoulder arthroplasty are rapidly increasing in the UK with 5221 cases recorded on the National Joint Registry (NJR) in 2015, a rise of greater than 100% since 2012.1,2 As the volume of procedures increases, more attention is focused on improving perioperative care to optimise patient outcomes and limit complications. Several large studies from the USA have examined the transfusion rate following shoulder arthroplasty, but at present no data have been published from a UK centre and data from the USA may not be generalisable to the population and healthcare setting in the UK.

The reported rate of blood transfusion following shoulder arthroplasty varies from 4.5 to 43%, with more recent work reporting rates at the lower end of this range.39 This compares favourably to transfusion rates of 16–58% following hip and knee arthroplasty.1013 Transfusion in patients undergoing shoulder arthroplasty has been shown to be associated with a higher risk of medical complications, including myocardial infarction, pneumonia, thromboembolic event as well has higher rates of local complication including peri-prosthetic infection.1,4

Previous studies have attempted to identify risk factors for transfusion in shoulder arthroplasty patients. Padegimas et al.4 reported that preoperative haematocrit and surgery for post-traumatic arthritis were both significantly associated with an increased transfusion risk, with other studies suggesting that age, female sex, ischaemic heart disease and the use of cement were all implicated.5,7,8 Padegimas et al.4 also reported that preoperative haematocrit of 0.396 or lower has a sensitivity of 90% in predicting transfusion following shoulder arthoplasty.9

The purpose of this study was to examine the transfusion rate following shoulder arthroplasty in a high volume UK centre, which does not routinely use tranexamic acid for these cases, and to identify risk factors for transfusion.

Materials and methods

A consecutive series of shoulder arthroplasties performed at the host institution, a tertiary referral upper limb unit, between January 2012 and March 2017 was identified. Patients were included if they underwent any form of shoulder arthroplasty, including anatomic total shoulder replacement, reverse total shoulder replacement, hemiarthroplasty and revision procedures for all indications. Patients were excluded if they received tranexamic acid during the perioperative period (n = 16).

A review of case notes, online patient records, operation note and relevant anaesthetic charts was made to collect patient demographic data, details of co-morbidities, preoperative/post-operative blood results and details regarding timing and quantity of any transfusion given. Local blood transfusion protocols state that a transfusion trigger of 70 g/l should be used if patients are asymptomatic, or 80 g/l if patients are symptomatic or have a history of ischaemic heart disease.

Univariable analysis (unpaired T-test for continuous variables, Chi squared or Fisher’s exact test for categorical data based on size of expected values) was used to evaluate the significance of all measured variables. Multivariable regression analysis was performed using GraphPad InStat and Prism (GraphPad Software Inc., La Jolla, CA, USA). Significance was determined when p < 0.05. No cases had missing data, therefore multiple regression analysis was performed on all cases. The dependent variable was whether transfusion was received or not, the independent variables were the age at intervention, procedure type, indication for intervention, gender, preoperative haemoglobin, post-operative haemoglobin, change between pre- and post-operative haemoglobin, preoperative haematocrit, post-operative haematocrit, ASA grade and laterality. The R2 values were inspected to determine if multicollinearity was a problem in the model, if the R2 value was >0.9 then the included values were rationalised. This led to the exclusion of the post-operative haemoglobin and post-operative haematocrit (with the preoperative values and the haemoglobin drop being retained).

This study was performed under the jurisdiction of the HRA and their decision-making tool indicates that ethical approval is not required for the current study or study design.

Results

During the period January 2012–March 2017, 553 arthroplasties were carried out in 490 patients. Of these 16 patients were given perioperative tranexamic acid and therefore excluded, leaving 537 arthroplasties in 474 patients eligible for analysis. There were 382 procedures carried out in female patients (71%) and 155 in males (29%), overall the mean age was 71.6 years (24–93). Twenty-one of 537 shoulder arthroplasties required a perioperative transfusion (4%). Demographic details for all patients included are provided in Table 1.

Table 2.

Multiple regression models investigating the risk of transfusion.

Variable Coefficient 95% Confidence interval t ratio p value
Age at operation 0.0007 −0.001 to 0.002 0.767 0.444
Procedure type −0.0194 −0.043 to 0.004 1.618 0.106
Indication for surgery 0.0038 −0.007 to 0.015 0.699 0.485
Gender −0.0240 −0.061 to 0.013 1.256 0.210
Preoperative haemoglobin −0.0012 −0.004 to 0.002 0.753 0.452
Change from pre- to post-operative haemoglobin 0.0063 0.005 to 0.008 8.166 <0.0001
Preoperative haematocrit −1.050 −2.185 to 0.084 1.814 0.070
ASA grade 0.0266 0.001 to 0.052 2.075 0.039
Laterality 0.010 −0.021 to 0.040 0.622 0.534

ASA: American Society of Anaesthesiologist score.

Table 1.

Demographic data of 474 patients undergoing 537 procedures.

Variable All procedures Transfusion No transfusion P value
No. of cases 537 21 516
Age 71.6 77.4 71.3 0.005
Gender 0.015
 Male 155 3 152
 Female 382 18 364
Pre-op Hb (g/L) 132 119 132 <0.001
Mean Hb drop (g/l) 23 38 22 <0.001
Pre-op Hct 0.4 0.36 0.4 <0.001
Pre-op Hct <0.001
 <0.396 235 18 217
 >0.396 302 3 299
Laterality 0.65
 Right 300 13 287
 Left 237 8 229
Procedure 0.13
 Anatomic 235 6 229
 Reverse 224 14 210
 Hemiarthroplasty 30 0 30
 Revision 48 1 47
Indication 0.14
 OA 258 4 254
 Cuff arthropathy 136 8 128
 AVN 16 2 15
 Acute trauma 6 0 6
 Post trauma 40 4 36
 RA 33 2 31
 Revision 48 1 46
ASA <0.001
 1 52 0 52
 2 259 4 255
 3 217 13 204
 4 9 4 5

ASA: American Society of Anaesthesiologist score.

The most common procedure was a primary anatomic total shoulder replacement, representing 235 (44%) of the cases, followed by reverse total shoulder replacement (224 cases; 42%), hemiarthoplasty (30 cases; 6%) and there were 48 revision procedures (9%). Of the 537 procedures undertaken, 258 were for osteoarthritis (48%), 136 for rotator cuff arthropathy (25%), 46 for trauma or trauma sequelae (9%), 33 for rheumatoid arthritis (6%) and 16 for avascular necrosis (3%).

A total of 39 units of packed red cells were transfused in 21 patients at a mean of three days post-op. One transfusion was given intra-operatively. Univariate analysis suggested an association between increasing age, preoperative haemoglobin, preoperative haematocrit, perioperative drop in haemoglobin and ASA with the risk of receiving a transfusion. Preoperative haematocrit was analysed both as a continuous variable, and as a categorical variable of either less or greater than 0.396 based on the work by Padegimas et al.4 Using preoperative haematocrit of less than 0.396 as an independent predictor of transfusion would have identified 18/21 transfusions, a sensitivity of 86%. Many of these variables were not found to be significant on multivariable analysis.

The multiple regression model for whether patients required transfusion or not showed a significant relationship (p < 0.0001). The change between pre- and post-operative haemoglobin (p < 0.0001) and the ASA grade (p < 0.039) was significantly associated with the risk of transfusion. The other variables included (age at intervention, procedure type, indication for intervention, gender, preoperative haemoglobin, preoperative haematocrit and laterality) did not (p = 0.07–0.53).

Discussion

This study reports an overall transfusion rate of 3.9% following 537 shoulder arthroplasty procedures. The demographic characteristics of the population studied are comparable both to previous published work and to the data reported by the NJR of England, Wales and Northern Ireland. Univariate analysis suggested that increasing age, female sex, lower preoperative haemoglobin and haematocrit, higher perioperative drop in haemoglobin and higher ASA grade were all significantly associated with transfusion risk. On multivariate analysis only the perioperative drop in haemoglobin and the ASA grade remained significant predictors of perioperative transfusion.

Historical studies have shown very high rates of transfusion following shoulder arthroplasty, with Gruson et al.9 reporting a transfusion rate of 43%. More recent work has shown greatly decreased rates of transfusion with Padegimas et al.,4 Kandil et al.5 and Gruson et al.9 reporting rates of 4.5, 6.1 and 7.4%, respectively. The transfusion rate of 3.9% reported here is lower than previously recorded rates, but in keeping with the more recent publications. The low transfusion rate reported could be influenced by several factors. First, institutional protocols determining when patients require a transfusion may vary, our institution advises transfusion when the haemoglobin is less than 70 g/l, or when the value is less than 80 g/l and the patient is symptomatic or has a history of ischaemic heart disease. Patients who are found to be anaemic at preoperative assessment are referred for further investigation, with surgery often delayed in these cases whilst preoperative optimisation is carried out. This occasionally leads to preoperative iron supplementation either orally or via intravenous infusion.

In hip and knee arthroplasty, the use of perioperative tranexamic acid is commonplace, and in recent years consideration has been given to its use in shoulder arthroplasty. Multiple randomised controlled trials have found that tranexamic acid use during shoulder arthroplasty decreases intra-operative blood loss, drop in haemoglobin and transfusion requirement.3,6 A meta-analysis on the subject concluded that tranexamic acid use was associated with a lower transfusion requirement and no increase in thrombotic events.10 With transfusion rates as low as 3.9% surgeons could question the case for blanket use of tranexamic acid. However, given the increased complication risk associated with transfusion,1 its confirmed role in reducing perioperative blood loss and favourable side effect profile10 there is clearly a role for perioperative tranexamic acid in shoulder arthroplasty.

A key step in the prevention of transfusion is identifying the patients most at risk. Padegimas et al.4 reported that preoperative haematocrit and surgery for post-traumatic arthritis were both independent risk factors for transfusion, going on to state that a preoperative haematocrit threshold of <0.396 had a 90% sensitivity for identifying patients who would require a transfusion. In this analysis preoperative haematocrit appeared to show a significant association with transfusion in univariate analysis, but no significant association was demonstrated between transfusion and either preoperative haematocrit or indication for surgery on multivariable analysis. Using a preoperative haematocrit threshold of <0.396 identified 18 out 21 (86%) of transfusions in this study, patients with a preoperative haematocrit of >0.396 had a 3/302 (1%) risk of transfusion.

Analysis of risk factors for transfusion by Kandil et al.,5 Ahmadi et al.7 and Hardy et al.8 identified increasing age, female sex, low preoperative haemoglobin, increased surgical blood loss and patient co-morbidities to be significantly associated with transfusion risk. Whilst univariate analysis suggested a positive association with age, gender and preoperative haemoglobin, no association was demonstrated on multiple variable analysis. The only positive predictors of transfusion risk on multivariable analysis were the perioperative drop in haemoglobin and the patients ASA grade.

The strengths of this paper are that it is a large comprehensive, consecutive series of shoulder arthroplasty cases from a single UK centre with a low rate of case exclusion. It must be stated that the numbers are small when compared to national population-level studies from the USA. It is also a strength that this is the only work of this nature to have been done on a UK shoulder arthroplasty population. The limitations are that this was a retrospective study based on case note review, and the number of cases may have been too small to detect significant associations on multivariate analysis. These cases were performed in a high-volume UK centre so results may not be generalisable to all UK centres performing shoulder arthroplasty. The study design used here is able to demonstrate an association between the considered variables and the risk of receiving a transfusion but is not able to definitively prove causation.

Conclusions

This study reports a low transfusion rate following shoulder arthroplasty of 3.9% in a UK population. Perioperative drop in haemoglobin and a patient’s ASA grade were both independent predictors of transfusion. This study did not confirm previous findings that age, gender, preoperative haemoglobin, preoperative haematocrit, procedure and indication for shoulder arthroplasty are predictors of transfusion.

Highlights

  • Low blood transfusion rate following shoulder arthroplasty compared to previous studies in literature

  • Increased perioperative drop in haemoglobin and higher ASA grade associated with increased risk of transfusion

Level of evidence – 2b Individual cohort study

Authors’ contributions

All authors finally approved the manuscript and agree to be accountable for all aspects of the work.

PJD: Conception, design, data acquisition, analysis and interpretation; drafting and revising manuscript

JVK: Data acquisition; revising manuscript

PASM, INP, PPS: Conception, data interpretation; revising manuscript

MRW: Data analysis and interpretation; drafting and revising manuscript

MAC: Conception, design, data interpretation; drafting and revising manuscript

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Review and Patient Consent

This study was performed under the jurisdiction of the HRA and their decision-making tool indicates that ethical approval is not required for the current study or study design.

References

  • 1.Grier AJ, Bala A, Penrose CT, et al. Analysis of complication rates following perioperative transfusion in shoulder arthroplasty. J Shoulder Elbow Surg 2017; 26: 1203–1209. [DOI] [PubMed] [Google Scholar]
  • 2.Board TNE. The 13th Annual Report of the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Hemel Hempstead, UK: The National Joint Registry, 2016, http://www.njrcentre.org.uk.
  • 3.Gillespie R, Shishani Y, Joseph S, et al. Neer Award 2015: a randomized, prospective evaluation on the effectiveness of tranexamic acid in reducing blood loss after total shoulder arthroplasty. J Shoulder Elbow Surg 2015; 24: 1679–1684. [DOI] [PubMed] [Google Scholar]
  • 4.Padegimas EM, Clyde CT, Zmistowski BM, et al. Risk factors for blood transfusion after shoulder arthroplasty. Bone Joint J 2016; 98: 224–228. [DOI] [PubMed] [Google Scholar]
  • 5.Kandil A, Griffin JW, Novicoff WM, et al. Blood transfusion after total shoulder arthroplasty: which patients are at high risk? Int J Shoulder Surg 2016; 10: 72–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Vara AD, Koueiter DM, Pinkas DE, et al. Intravenous tranexamic acid reduces total blood loss in reverse total shoulder arthroplasty: a prospective, double-blinded, randomized, controlled trial. J Shoulder Elbow Surg 2017; 26: 1383–1389. [DOI] [PubMed] [Google Scholar]
  • 7.Ahmadi S, Lawrence TM, Sahota S, et al. The incidence and risk factors for blood transfusion in revision shoulder arthroplasty: our institution’s experience and review of the literature. J Shoulder Elbow Surg 2014; 23: 43–48. [DOI] [PubMed] [Google Scholar]
  • 8.Hardy JC, Hung M, Snow BJ, et al. Blood transfusion associated with shoulder arthroplasty. J Shoulder Elbow Surg 2013; 22: 233–239. [DOI] [PubMed] [Google Scholar]
  • 9.Gruson KI, Accousti KJ, Parsons BO, et al. Transfusion after shoulder arthroplasty: an analysis of rates and risk factors. J Shoulder Elbow Surg 2009; 18: 225–230. [DOI] [PubMed] [Google Scholar]
  • 10.Sun C-X, Zhang L, Mi L-D, et al. Efficiency and safety of tranexamic acid in reducing blood loss in total shoulder arthroplasty: a systematic review and meta-analysis. Medicine 2017; 96: e7015–e7015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Parvizi J, Chaudhry S, Rasouli MR, et al. Who needs autologous blood donation in joint replacement? J Knee Surg 2011; 24: 25–31. [DOI] [PubMed] [Google Scholar]
  • 12.Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81: 2–10. [DOI] [PubMed] [Google Scholar]
  • 13.Guerin S, Collins C, Kapoor H, et al. Blood transfusion requirement prediction in patients undergoing primary total hip and knee arthroplasty. Transfus Med 2007; 17: 37–43. [DOI] [PubMed] [Google Scholar]

Articles from Shoulder & Elbow are provided here courtesy of SAGE Publications

RESOURCES